Form 8-K - Current report:
SEC Accession No. 0001493152-21-016077
Filing Date
2021-07-02
Accepted
2021-07-02 16:50:09
Documents
5
Period of Report
2021-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 37016
2 ex1-1.htm EX-1.1 275752
3 ex5-1.htm EX-5.1 21075
4 ex5-1_001.jpg GRAPHIC 2712
5 ex5-1_002.jpg GRAPHIC 2224
  Complete submission text file 0001493152-21-016077.txt   342294
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 211070962
SIC: 7389 Services-Business Services, NEC